343 related articles for article (PubMed ID: 26238192)
1. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes.
Song X; Ren Y; Zhang J; Wang G; Han X; Zheng W; Zhen L
Oncol Rep; 2015 Oct; 34(4):1953-60. PubMed ID: 26238192
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis.
Qiu X; Li Z; Han X; Zhen L; Luo C; Liu M; Yu K; Ren Y
Theranostics; 2019; 9(9):2618-2636. PubMed ID: 31131057
[TBL] [Abstract][Full Text] [Related]
3. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
4. Delivery of doxorubicin loaded P18 conjugated-poly(2-ethyl-oxazoline)-DOPE nanoliposomes for targeted therapy of breast cancer.
Bolat ZB; Nezir AE; Devrim B; Zemheri E; Gulyuz S; Ozkose UU; Yilmaz O; Bozkir A; Telci D; Sahin F
Toxicol Appl Pharmacol; 2021 Oct; 428():115671. PubMed ID: 34391753
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
7. A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo.
Taghdisi SM; Danesh NM; Ramezani M; Yazdian-Robati R; Abnous K
Mol Pharm; 2018 May; 15(5):1972-1978. PubMed ID: 29669200
[TBL] [Abstract][Full Text] [Related]
8. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
9. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
10. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
12. Targeted co-delivery of FOXM1 aptamer and DOX by nucleolin aptamer-functionalized pH-responsive biocompatible nanodelivery system to enhance therapeutic efficacy against breast cancer: in vitro and in vivo.
Masoudi M; Taghdisi SM; Hashemitabar G; Abnous K
Drug Deliv Transl Res; 2024 Jun; 14(6):1535-1550. PubMed ID: 38161196
[TBL] [Abstract][Full Text] [Related]
13. The synergy between structural stability and DNA-binding controls the antibody production in EPC/DOTAP/DOPE liposomes and DOTAP/DOPE lipoplexes.
de la Torre LG; Rosada RS; Trombone AP; Frantz FG; Coelho-Castelo AA; Silva CL; Santana MH
Colloids Surf B Biointerfaces; 2009 Oct; 73(2):175-84. PubMed ID: 19540734
[TBL] [Abstract][Full Text] [Related]
14. Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study.
Nikpoor AR; Jaafari MR; Zamani P; Teymouri M; Gouklani H; Saburi E; Darban SA; Badiee A; Bahramifar A; Fasihi-Ramandi M; Taheri RA
Int J Pharm; 2019 Aug; 567():118492. PubMed ID: 31271815
[TBL] [Abstract][Full Text] [Related]
15. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
16. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
[TBL] [Abstract][Full Text] [Related]
17. Cell-penetrating Peptide-coated Liposomes for Drug Delivery Across the Blood-Brain Barrier.
Yuan BO; Zhao Y; Dong S; Sun Y; Hao F; Xie J; Teng L; Lee RJ; Fu Y; Bi YE
Anticancer Res; 2019 Jan; 39(1):237-243. PubMed ID: 30591464
[TBL] [Abstract][Full Text] [Related]
18. Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.
Chowdhury N; Chaudhry S; Hall N; Olverson G; Zhang QJ; Mandal T; Dash S; Kundu A
AAPS PharmSciTech; 2020 Jul; 21(6):202. PubMed ID: 32696338
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
20. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
